Real‐world evidence for amyloid‐targeted therapies: Lecanemab and donanemab
Authors:
Open Access
- 1 July 2026
- journal article
- research article
- Published by Wiley in Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
- Vol. 18 (3) , e70404
Abstract
INTRODUCTION: Real‐world safety data on amyloid‐targeted therapies in early Alzheimer's disease remain limited, particularly for modified donanemab titration and direct lecanemab–donanemab comparisons. METHODS: Retrospective review of 172 amyloid‐positive patients treated with lecanemab ( n = 89) or donanemab (original titration n = 21; modified n = 62). The cohort included patients with ≥2 chronic comorbidities (72.7%), systemic autoimmune or hematologic disorders, and concurrent immunomodulators. RESULTS: Amyloid‐related imaging abnormalities (ARIA) occurred in 11.2% (10/89) with lecanemab and 13.3% (11/83) with donanemab—less than in pivotal trials. Modified donanemab titration reduced ARIA versus the original protocol (8.1% vs 28.6%; p = 0.03) and TRAILBLAZER‐ALZ 6 (23.6%). No anaphylaxis occurred. Surveillance magnetic resonance imaging captured 95.2% of ARIA events. Within‐center comparison showed comparable safety between lecanemab and modified‐titration donanemab (all p ’s > 0.40). IRRs occurred in 12.0% (donanemab) and 9.0% (lecanemab). DISCUSSION: In a real‐world cohort representing patients excluded from trials, ARIA and IRR rates matched or improved upon pivotal trials, supporting safe ATT use under FDA‐approved MRI intervals.Keywords
This publication has 28 references indexed in Scilit:
- Long‐term safety and efficacy of lecanemab in early Alzheimer's disease: Results from the clarity AD open‐label extension studyAlzheimer's & Dementia, 2025
- Influence of patient characteristics on efficacy and safety of anti-amyloid monoclonal antibodies in Alzheimer’s disease: A systematic review and meta-analysisAgeing Research Reviews, 2025
- Anti-amyloid immunotherapies for Alzheimer’s disease: Administration, side effects, and overall frameworkGeriatric Nursing, 2025
- Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer DiseaseJAMA Neurology, 2025
- Modified titration of donanemab reduces ARIA risk and maintains amyloid reductionAlzheimer's & Dementia, 2025
- Amyloid‐related imaging abnormalities (ARIA): diagnosis, management, and care in the setting of amyloid‐modifying therapyAnnals of Clinical and Translational Neurology, 2024
- Donanemab in Early Symptomatic Alzheimer DiseaseJAMA, 2023
- ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's diseaseAlzheimer's & Dementia: Translational Research & Clinical Interventions, 2023
- The comparative efficacy and safety of cholinesterase inhibitors in patients with mild‐to‐moderate Alzheimer's disease: a Bayesian network meta‐analysisInternational Journal of Geriatric Psychiatry, 2015
- Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable WorkgroupAlzheimer's & Dementia, 2011